Ocular Therapeutix (NASDAQ:OCUL) Shares Up 5.8% - Still a Buy?

Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Get Free Report) traded up 5.8% on Monday . The company traded as high as $7.74 and last traded at $7.74. 136,728 shares traded hands during trading, a decline of 91% from the average session volume of 1,523,282 shares. The stock had previously closed at $7.31.

Analysts Set New Price Targets

OCUL has been the topic of several research analyst reports. JMP Securities set a $19.00 price objective on shares of Ocular Therapeutix in a research report on Tuesday, March 4th. HC Wainwright restated a "buy" rating and issued a $15.00 price target on shares of Ocular Therapeutix in a research report on Tuesday, March 4th. William Blair initiated coverage on Ocular Therapeutix in a research note on Tuesday, April 8th. They set an "outperform" rating for the company. Needham & Company LLC restated a "buy" rating and issued a $15.00 price target on shares of Ocular Therapeutix in a research note on Tuesday, April 8th. Finally, Royal Bank of Canada initiated coverage on Ocular Therapeutix in a research report on Tuesday, March 18th. They issued an "outperform" rating and a $17.00 target price for the company. One research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat, Ocular Therapeutix has an average rating of "Moderate Buy" and an average target price of $16.38.

Ocular Therapeutix Stock Performance

The company has a debt-to-equity ratio of 0.19, a quick ratio of 12.94 and a current ratio of 13.01. The stock has a fifty day simple moving average of $7.26 and a two-hundred day simple moving average of $8.48. The stock has a market capitalization of $1.23 billion, a price-to-earnings ratio of -5.84 and a beta of 1.49.

Ocular Therapeutix (NASDAQ:OCUL - Get Free Report) last issued its earnings results on Monday, March 3rd. The biopharmaceutical company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.05). Ocular Therapeutix had a negative net margin of 283.74% and a negative return on equity of 45.18%. The firm had revenue of $17.08 million during the quarter, compared to analyst estimates of $16.89 million. Analysts forecast that Ocular Therapeutix, Inc. will post -0.98 earnings per share for the current fiscal year.

Insider Buying and Selling at Ocular Therapeutix

In other news, insider Donald Notman sold 11,119 shares of Ocular Therapeutix stock in a transaction dated Tuesday, February 4th. The shares were sold at an average price of $7.81, for a total value of $86,839.39. Following the completion of the transaction, the insider now owns 193,444 shares in the company, valued at $1,510,797.64. This trade represents a 5.44 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Pravin Dugel sold 21,475 shares of the business's stock in a transaction on Monday, February 24th. The shares were sold at an average price of $6.87, for a total value of $147,533.25. Following the sale, the insider now owns 3,520,318 shares in the company, valued at approximately $24,184,584.66. The trade was a 0.61 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 38,895 shares of company stock worth $283,772. Insiders own 3.50% of the company's stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. GF Fund Management CO. LTD. purchased a new stake in shares of Ocular Therapeutix during the 4th quarter valued at $28,000. Atlas Capital Advisors Inc. bought a new position in Ocular Therapeutix in the fourth quarter worth about $43,000. AlphaQuest LLC purchased a new position in Ocular Therapeutix during the fourth quarter valued at $53,000. GAMMA Investing LLC boosted its position in shares of Ocular Therapeutix by 6,760.0% in the 1st quarter. GAMMA Investing LLC now owns 8,232 shares of the biopharmaceutical company's stock worth $60,000 after purchasing an additional 8,112 shares in the last quarter. Finally, Tower Research Capital LLC TRC boosted its stake in Ocular Therapeutix by 2,045.0% in the 4th quarter. Tower Research Capital LLC TRC now owns 8,859 shares of the biopharmaceutical company's stock worth $76,000 after purchasing an additional 8,446 shares in the last quarter. 59.21% of the stock is owned by institutional investors.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.